Approximately 70% of KCNB1-related epilepsy cases are drug refractory.[2] Patient 1 in the present report was initially treated with sodium valproate monotherapy, and generalized myoclonic seizures were reduced by >50%. Here, KCNB1 is linked to epilepsy.